octocenter-logo

Metastatic Uveal Melanoma Treatment

Metastatic Uveal Melanoma Treatment

A rare and aggressive form of cancer, metastatic uveal melanoma develops in the pigment cells of the eye. It occurs when cancer cells from the uveal melanoma spread to other parts of the body, most commonly the liver. Metastatic uveal melanoma is known for its poor prognosis, as it tends to spread rapidly and is often resistant to treatment. Patients with this condition face a high risk of mortality. The disease typically presents with symptoms like blurry vision, eye pain, and changes in the appearance of the iris. Diagnosis involves a variety of imaging tests and biopsy. Understanding the biology and behavior of metastatic uveal melanoma is crucial for developing effective treatment strategies.

Surgical Treatment Options

Enucleation

Enucleation, the full surgical removal of the affected eyeball, is considered when dealing with a large, isolated tumor and sight preservation is deemed unfeasible or in cases where the tumor is causing severe discomfort**. It aims to eliminate the cancer by removing its primary source and reducing the chances of recurrence**. It is a significant and life-changing measure but can offer effective control of the local disease and improve survival chances. It is vital to provide the patient with adequate psychological support during this period to help cope with the physical and emotional consequences.

Local Tumor Resection

For metastatic uveal melanomas that are contained within the eye, local tumor resection is often applied. The surgeon removes the tumor while minimizing damage to healthy tissue surrounding it**. Primarily, it seeks to cut out the tumor and decrease the chance of its recurrence and development into metastases.** Following surgery, temporary vision changes and discomfort may occur, which can normally be managed using prescribed medication. As a surgical approach, local tumor resection has proven effective in preserving sight and controlling the disease locally, particularly when complemented by radiation therapy or targeted treatments. A multidisciplinary healthcare team should evaluate the patient's health and suitability before considering this surgical option.

Liver Resection

Should the cancer have migrated to the liver, a liver resection could be recommended. This technique involves surgically removing the tumor along with the portion of the liver where it has established. It aims to eradicate the tumors while continuing to support liver functionality. It's often more suitable for patients exhibiting minimal liver involvement and a generally sound health standing. The procedure might be undertaken via various routes, such as conventional surgery or employing minimally invasive techniques like laparoscopic or robotic-assisted surgery. A multitude of factors, including the liver metastases' size, number and position as well as the patient's overall health and other metastases can influence the decision to remove the liver. Selected patients might benefit from a potential cure and extended disease control from liver resection for metastatic uveal melanoma.

Non-Surgical Treatment Options

Radiation Therapy

Radiation therapy is a non-operative therapeutic technique used to curb the spread of metastatic uveal melanoma. It employs high-energy radiation, targeting and eliminating the diseased cells. External beam radiation therapy is often the preferred radiation treatment method, discharging radiation from an external device to aim precisely at the tumor while sparing surrounding healthy tissue. Plaque brachytherapy, another radiation treatment type involves the placement of a minuscule radioactive device in close proximity or onto the tumor for localized radiation release. The application of radiation therapy hinges on factors such as the tumor's characteristics and position. Possible side-effects include fatigue, skin alterations, and irritation in the radiated area. Nonetheless, radiation therapy has proven successful in tumor size reduction and managing metastatic uveal melanoma.

Targeted Therapy

Another non-surgical approach is targeted therapy, focusing specifically on the molecular attributes of the uveal melanoma cancer cells. Unlike traditional chemotherapy that indiscriminately affects healthy and cancer cells, targeted therapy employs drugs that seek to inhibit certain molecules or pathways crucial for cancer cell survival. For example, metastatic uveal melanoma often implicates molecular targets like protein GNAQ or GNA11. Targeted therapy seeks to interrupt the abnormal signaling pathways facilitating the melanoma growth and spread. This precision offers possible improved effectiveness and lesser side-effects compared to chemotherapy. Current scientific exploration and clinical trials are evaluating the efficiency of various targeted therapies and their possible combined use with other treatment modalities in enhancing patient outcomes.

metastatic uveal melanoma treatment

Immunotherapy

Immunotherapy is another non-invasive treatment alternative for metastatic uveal melanoma. It involves triggering the body's immune response to recognize and eradicate cancer cells. This method utilizes immune checkpoint inhibitors, like pembrolizumab and ipilimumab, which inhibit proteins that shield cancer cells from immune cells. Clinical trials indicate that immunotherapy may enhance survival rates and control disease progression in some patients, but its effectiveness is patient-dependent. Common side effects include fatigue, skin inflammation, and organ inflammation. Contemporary research seeks to identify potential biomarkers to forecast which patients might benefit most from this treatment. Overall, immunotherapy presents an optimistic treatment possibility against metastatic uveal melanoma, offering some reprieve to patients battling this aggressive cancer form.

Emerging Treatment Approaches

Cutting-edge therapeutic methods for metastatic uveal melanoma are under rigorous investigation with the aim of enhancing patient prognosis. Gene therapy is one such method, with its primary focus on pinpointing specific genes or introducing novel genes into malignant cells to curb their proliferation or provoke cell apoptosis. The notion of gene therapy carries a great deal of potential, yet necessitates deeper research to authenticate its efficacy and safety. The study of combined therapies is also underway - these involve the concurrent use of various treatment modalities for optimum outcomes. For instance, amalgamating radiation therapy with targeted therapy or immunotherapy could potentiate the treatments' success, potentially heightening survival rates. The role of clinical trials is invaluable in weighing up the efficiency and safety of newfangled treatment methods. By inscribing patients in meticulously orchestrated trials, scientific investigators can accumulate data on the advantages and drawbacks of novel treatments before they garner broader use. The determination and analysis of such avant-garde treatment approaches will aid the ceaseless endeavor to enhance results for patients struggling with metastatic uveal melanoma.

Bibliography

  1. Branisteanu, D. C., Bogdanici, C. M., Branisteanu, D. E., Maranduca, M. A., Zemba, M., Balta, F., ... & Moraru, A. D. (2021). Uveal melanoma diagnosis and current treatment options. Experimental and Therapeutic Medicine, 22(6), 1-8 (https://www.spandidos-publications.com/10.3892/etm.2021.10863)

  2. Sarode, D., McClay, T., Roberts, F., Connolly, J., Cauchi, P., & Chadha, V. (2023). Post-enucleation outcomes of patients with uveal melanoma in Scotland. Eye, 37(5), 988-994. (https://www.nature.com/articles/s41433-022-02280-3)

  3. Sayan, M., Mamidanna, S., Oncel, D., Jan, I., Vergalasova, I., Weiner, J., ... & Chundury, A. (2020). Clinical management of uveal melanoma: a comprehensive review with a treatment algorithm. Radiation Oncology Journal, 38(3), 162. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533402/)

  4. Rowcroft, A., Loveday, B. P., Thomson, B. N., Banting, S., & Knowles, B. (2020). Systematic review of liver directed therapy for uveal melanoma hepatic metastases. Hpb, 22(4), 497-505. (https://www.sciencedirect.com/science/article/pii/S1365182X19331934)

  5. Tsilimigras, D. I., Brodt, P., Clavien, P. A., Muschel, R. J., D'Angelica, M. I., Endo, I., ... & Pawlik, T. M. (2021). Liver metastases. Nature reviews Disease primers, 7(1), 27. (https://www.nature.com/articles/s41572-021-00261-6)

  6. Thompson, J. F., Faries, M. B., Friedman, E. B., Lee, J. E., & Balch, C. M. (2020). Surgical management of distant melanoma metastases. Cutaneous melanoma, 1359-1402. (https://link.springer.com/content/pdf/10.1007/978-3-030-05070-2_64.pdf)

  7. Wang, Y., Wang, M., Wu, H. X., & Xu, R. H. (2021). Advancing to the era of cancer immunotherapy. Cancer communications. (https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cac2.12178)

  8. Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020). Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nature Reviews Clinical Oncology, 17(4), 251-266. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272676/)

  9. Meric-Bernstam, F., Larkin, J., Tabernero, J., & Bonini, C. (2021). Enhancing anti-tumour efficacy with immunotherapy combinations. The Lancet. (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32598-8/fulltext)

  10. Masaoutis, C., Kokkali, S., & Theocharis, S. (2021). Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment. Expert opinion on investigational drugs, 30(5), 555-569. (https://www.researchgate.net/profile/Stefania-Kokkali/publication/349736681_Immunotherapy_in_uveal_melanoma_novel_strategies_and_opportunities_for_personalized_treatment/links/643865c74e83cd0e2fad3af6/Immunotherapy-in-uveal-melanoma-novel-strategies-and-opportunities-for-personalized-treatment)

  11. Dai, W., Liu, S., Wang, S., Zhao, L., Yang, X., Zhou, J., ... & Pan, J. (2021). Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma. Signal Transduction and Targeted Therapy, 6(1), 176. (https://www.nature.com/articles/s41392-021-00563-x)